Journal
PPAR RESEARCH
Volume 2016, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2016/2308249
Keywords
-
Categories
Funding
- Centros de Investigacion En Red (CIBER) [CB06/03/0018]
- Instituto de Salud Carlos III (ISCIII)
- ISCIII [PI11/01661]
- Consejeria de Innovacion, Ciencia y Empresa de la Junta de Andalucia [PI11-CTS-8181]
- European Regional Development Fund (FEDER)
- Servicio Andaluz de Salud, Junta de Andalucia, Spain [C0029-2014]
Ask authors/readers for more resources
The PPAR nuclear receptor family has acquired great relevance in the last decade, which is formed by three different isoforms (PPAR alpha, PPAR beta/delta, and PPAR gamma). Those nuclear receptors are members of the steroid receptor superfamily which take part in essential metabolic and life-sustaining actions. Specifically, PPARG has been implicated in the regulation of processes concerning metabolism, inflammation, atherosclerosis, cell differentiation, and proliferation. Thus, a considerable amount of literature has emerged in the last ten years linking PPARG signalling with metabolic conditions such as obesity and diabetes, cardiovascular disease, and, more recently, cancer. This review paper, at crossroads of basic sciences, preclinical, and clinical data, intends to analyse the last research concerning PPARG signalling in obesity and cancer. Afterwards, possible links between four interrelated actors will be established: PPARG, the vitamin D/VDR system, obesity, and cancer, opening up the door to further investigation and new hypothesis in this fascinating area of research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available